NCT04084184View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HGP1602 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

March 25, 2019

Study Completion Date

March 29, 2019

Conditions
Healthy
Interventions
DRUG

HGP1812

Dapagliflozin (Forxiga) 10mg

DRUG

HGP1602

Dapagliflozin 10mg

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04084184 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HGP1602 in Healthy Subjects | Biotech Hunter | Biotech Hunter